Dopamine

Dopamine

SCHEMBL3954271

Cl.Cl.NCCc1ccc(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1

The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 1.00
MAPT P10636 4/20 1.00
LMNA P02545 4/20 1.00
MAPK1 P28482 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
BLM P54132 3/20 1.00
ADRA2A P08913 2/20 1.00
DRD2 P14416 2/20 1.00
DRD1 P21728 2/20 1.00
DRD4 P21917 2/20 1.00
DRD5 P21918 2/20 1.00
SLC6A2 P23975 2/20 1.00
DRD3 P35462 2/20 1.00
RECQL P46063 2/20 1.00
SLC6A3 Q01959 2/20 1.00
GAA P10253 2/20 1.00
GFER P55789 2/20 1.00
PMP22 Q01453 2/20 1.00
TAAR1 Q96RJ0 3/20 0.95
ALDH1A1 P00352 3/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dopamine SCHEMBL40951 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL28324791 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL29636832 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL27754471 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL28285902 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL23704750 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL29831984 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL40952 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL30379446 1.00 KDM4E (1.00) KDM4EMAPTLMNAMAPK1TDP1
Dopamine SCHEMBL29201795 0.98 KDM4E (0.96) KDM4EMAPTLMNAMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122060312-A Polyether-based lithium battery packaging material and preparation method thereof 江苏利宏科技发展有限公司 2026-05-19 CN disclosed
CN-116327932-A Preparation method and application of pH response type bionic gold nano-drug for chemotherapy, thermotherapy and targeted therapy 河南大学 2023-06-27 CN disclosed
CN-114702713-B Preparation method of silver niobate fiber-doped polyvinylidene fluoride composite film 北京理工大学 2022-12-09 CN disclosed
CN-114344553-B Polyglutamic acid gastric acid-resistant hemostatic adhesive 南京工业大学 2022-11-25 CN disclosed
CN-110100045-B Reaction products of catechol compounds with functionalized co-reactive compounds for metal pretreatment applications 汉高股份有限及两合公司 2022-09-06 CN disclosed
CN-114702713-A Preparation method of silver niobate fiber-doped polyvinylidene fluoride composite film 北京理工大学 2022-07-05 CN disclosed
CN-112029068-B Polyurethane compound, preparation method thereof and biological binder 浙江德普斯医疗科技股份有限公司 2022-05-31 CN disclosed
CN-114344553-A Polyglutamic acid gastric acid-resistant hemostatic adhesive 南京工业大学 2022-04-15 CN disclosed
CN-114204028-A Preparation method of polydopamine-coated sodium-ion battery positive electrode material 南通金通储能动力新材料有限公司 2022-03-18 CN disclosed
EP-2830633-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER McMaster University (CA) 2015-02-04 EP disclosed
EP-2680853-A1 TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS McMaster University (CA) 2014-01-08 EP disclosed
WO-2013143000-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER MCMASTER UNIVERSITY (CA) 2013-10-03 WO disclosed
WO-2012116432-A1 TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS MCMASTER UNIVERSITY (CA) 2012-09-07 WO disclosed
EP-2023874-A4 METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OF RESTENOSIS BIOSEEK INC (US) 2009-07-08 EP disclosed
EP-2023874-A2 METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OF RESTENOSIS Bioseek, Inc. (US) 2009-02-18 EP disclosed
WO-2007143211-A2 METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OF RESTENOSIS BIOSEEK, INC. (US) 2007-12-13 WO disclosed